Literature DB >> 30110580

Ibalizumab in Multidrug-Resistant HIV - Accepting Uncertainty.

Virginia Sheikh1, Jeffrey S Murray1, Adam Sherwat1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30110580     DOI: 10.1056/NEJMp1808729

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  5 in total

Review 1.  Advances in Long-Acting Agents for the Treatment of HIV Infection.

Authors:  Aadia I Rana; Jose R Castillo-Mancilla; Karen T Tashima; Raphael L Landovitz
Journal:  Drugs       Date:  2020-04       Impact factor: 9.546

2.  Human Immunodeficiency Virus Persistence in the Spleen: Opportunities for Pharmacologic Intervention.

Authors:  Aaron S Devanathan; Angela D M Kashuba
Journal:  AIDS Res Hum Retroviruses       Date:  2021-02-22       Impact factor: 1.723

3.  Characterization of a human monoclonal antibody generated from a B-cell specific for a prefusion-stabilized spike protein of Middle East respiratory syndrome coronavirus.

Authors:  Jang-Hoon Choi; Hye-Min Woo; Tae-Young Lee; So-Young Lee; Sang-Mu Shim; Woo-Jung Park; Jeong-Sun Yang; Joo Ae Kim; Mi-Ran Yun; Dae-Won Kim; Sung Soon Kim; Yi Zhang; Wei Shi; Lingshu Wang; Barney S Graham; John R Mascola; Nanshuang Wang; Jason S McLellan; Joo-Yeon Lee; Hansaem Lee
Journal:  PLoS One       Date:  2020-05-08       Impact factor: 3.240

4.  Generation of HIV-resistant cells with a single-domain antibody: implications for HIV-1 gene therapy.

Authors:  Hongliang Jin; Xiaoran Tang; Li Li; Yue Chen; Yuanmei Zhu; Huihui Chong; Yuxian He
Journal:  Cell Mol Immunol       Date:  2021-01-18       Impact factor: 11.530

Review 5.  Ibalizumab: A Review in Multidrug-Resistant HIV-1 Infection.

Authors:  Hannah A Blair
Journal:  Drugs       Date:  2020-02       Impact factor: 11.431

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.